Back to Search Start Over

Technology evaluation: Belatacept, Bristol-Myers Squibb.

Authors :
Vanhove B
Soulillou JP
Source :
Current opinion in molecular therapeutics [Curr Opin Mol Ther] 2005 Aug; Vol. 7 (4), pp. 384-93.
Publication Year :
2005

Abstract

Bristol-Myers Squibb is developing belatacept, a soluble fusion protein of the B7-binding domain of CTLA4 with amino acid changes A29Y and L104E and an Ig tail, which inhibits lymphocyte co-stimulation through CD28, for the potential treatment of solid organ transplant rejection. Belatacept is currently undergoing phase III clinical trials.

Subjects

Subjects :
Antigens, CD
CTLA-4 Antigen
Clinical Trials, Phase II as Topic
Genetic Engineering
Humans
Kidney Transplantation
Randomized Controlled Trials as Topic
Antigens, Differentiation therapeutic use
Arthritis, Rheumatoid drug therapy
Graft Rejection drug therapy
Immunosuppressive Agents therapeutic use

Details

Language :
English
ISSN :
1464-8431
Volume :
7
Issue :
4
Database :
MEDLINE
Journal :
Current opinion in molecular therapeutics
Publication Type :
Academic Journal
Accession number :
16121705

Tools

Authors Abstract Subjects Details